Big Pharma’s Strategic Pivot to China’s Innovation Hub
By 2026, pharmaceutical companies are increasingly prioritizing China for biotechnology innovation and manufacturing, driven by regulatory improvements, talent availability, and a large domestic market for treatments like orforglipron. This strategic shift aims to secure supply…